Drugs that contain Fish Oil Triglycerides
1. Omegaven patents expiration
OMEGAVEN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(11 months from now) | |
| US9629821 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 7 months from now) | |
| US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 27, 2023 |
| Orphan Drug Exclusivity (ODE) | Jul 27, 2025 |
NCE-1 date: 2022-07-27
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver dis...
Dosage: EMULSION;INTRAVENOUS
More Information on Dosage
OMEGAVEN family patents
